ChronoScale Corporation Common Stock (NASDAQ:CHRN) Issues Earnings Results

ChronoScale Corporation Common Stock (NASDAQ:CHRN) issued its quarterly earnings data on Tuesday. The company reported ($3.89) EPS for the quarter, FiscalAI reports. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The company had revenue of $18.09 million during the quarter.

ChronoScale Corporation Common Stock Stock Performance

ChronoScale Corporation Common Stock stock opened at $17.64 on Thursday. The business has a 50 day moving average of $17.21 and a 200-day moving average of $12.03. The company has a market capitalization of $62.85 million, a P/E ratio of -3.28 and a beta of 0.99. ChronoScale Corporation Common Stock has a 1 year low of $2.91 and a 1 year high of $28.20. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.55 and a quick ratio of 1.03.

Institutional Trading of ChronoScale Corporation Common Stock

Institutional investors have recently modified their holdings of the business. Roble Belko & Company Inc increased its position in shares of ChronoScale Corporation Common Stock by 104.5% during the first quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock worth $25,000 after buying an additional 1,195 shares during the period. Geode Capital Management LLC boosted its position in ChronoScale Corporation Common Stock by 68.9% during the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares during the last quarter. Virtu Financial LLC bought a new stake in ChronoScale Corporation Common Stock during the third quarter valued at $57,000. Shay Capital LLC acquired a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth about $67,000. Finally, Citadel Advisors LLC acquired a new stake in ChronoScale Corporation Common Stock during the 3rd quarter worth about $198,000. Institutional investors own 6.42% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a research note on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $6.00.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.